{"id":2110,"date":"2024-08-14T10:08:01","date_gmt":"2024-08-14T10:08:01","guid":{"rendered":"https:\/\/negargetni.com\/?page_id=2110"},"modified":"2026-02-25T17:21:06","modified_gmt":"2026-02-25T15:21:06","slug":"communiques-de-presse","status":"publish","type":"page","link":"https:\/\/integragen.com\/en\/investisseurs\/communiques-de-presse\/","title":{"rendered":"Financial Communications"},"content":{"rendered":"
\n
<\/div>\n\n\n\n

Financial Communications<\/h2>\n\n\n\n

2026<\/h4>\n\n\n\n
20\/02\/2026<\/td>IntegraGen - 2025 sales and cash position<\/a><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

2025<\/h4>\n\n\n\n
29\/10\/2025<\/td>IntegraGen - Operating expenses down 20% and cash position at \u20ac1.7m at June 30, 2025<\/a><\/td><\/tr>
02\/07\/2025<\/td>IntegraGen - Sales of \u20ac2.5m and cash position of \u20ac2.1m<\/a><\/td><\/tr>
29\/04\/2025<\/td>IntegraGen - Annual results 2024<\/a><\/td><\/tr>
15\/01\/2025<\/td>IntegraGen - 2024 sales and cash position<\/a><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

2024<\/h4>\n\n\n\n
17\/10\/2024<\/td>IntegraGen - H1 2024 results - Sales up 6% on a like-for-like basis (excluding SeqOIA) and profitability maintained<\/a><\/td><\/tr>
18\/07\/2024<\/td>IntegraGen - Sales up 6% and cash position of \u20ac2.8m<\/a><\/td><\/tr>
18\/04\/2024<\/td>IntegraGen - 2023 annual results: 5% decline in revenues and positive EBITDA<\/a><\/td><\/tr>
13\/01\/2024<\/td>IntegraGen - 2023 sales and cash position<\/a><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

2023<\/h4>\n\n\n\n
19\/10\/2023<\/td>IntegraGen - H1 2023 results - Sales down 13% and resilient profitability<\/a><\/td><\/tr>
13\/07\/2023<\/td>IntegraGen - First-half 2023 sales of \u20ac5.6m, down 13% on H1 2022, and cash position of \u20ac4.3m<\/a><\/td><\/tr>
24\/04\/2023<\/td>IntegraGen - 2022 annual results: 16% revenue growth and positive EBITDA<\/a><\/td><\/tr>
13\/01\/2023<\/td>IntegraGen - 2022 sales and cash position<\/a><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

2022<\/h4>\n\n\n\n
18\/10\/2022<\/td>Half-year results 2022 - Strong growth in 35% revenues and improved profitability <\/a><\/td><\/tr>
13\/07\/2022<\/td>First-half 2022 sales of \u20ac6.4m, up +34% on H1 2021, and cash position of \u20ac4.5m<\/a><\/td><\/tr>
29\/04\/2022<\/td>IntegraGen - 2021 annual results: strong 201TP3Q growth in revenues from ongoing operations and marked improvement in profitability <\/a><\/td><\/tr>
14\/01\/2022<\/td>IntegraGen - 2021 sales and cash position<\/a><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

2021<\/h4>\n\n\n\n
08\/10\/2021<\/td>IntegraGen - Half-year results 2021<\/a><\/td><\/tr>
16\/07\/2021<\/td>First-half 2021 sales of \u20ac4.8m, up +2% on 2020, and cash position of \u20ac4.3m<\/a><\/td><\/tr>
16\/04\/2021<\/td>Integragen - 2020 annual results: growth in revenues from ongoing operations (+101TP3Q) and EBITDA close to breakeven for the year<\/a><\/td><\/tr>
12\/01\/2020<\/td> IntegraGen - 2020 sales and cash position<\/a><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

2020<\/h4>\n\n\n\n
16\/11\/2020<\/td>Successful friendly takeover bid by OncoDNA for IntegraGen shares<\/a><\/td><\/tr>
18\/09\/2020<\/td>IntegraGen - 1st half 2020 results<\/a><\/td><\/tr>
09\/07\/2020<\/td>Agreement on a friendly takeover bid by OncoDNA for IIntegraGen<\/a><\/td><\/tr>
03\/04\/2020<\/td>IntegraGen - Annual results 2019<\/a><\/td><\/tr>
26\/03\/2020<\/td>IntegraGen announces agreement with leading US cancer center to use MERCURY\u2122<\/a><\/td><\/tr>
11\/03\/2020<\/td>IntegraGen renews partnership agreement with Institut Pasteur<\/a><\/td><\/tr>
10\/01\/2020<\/td>IntegraGen - 2019 sales and cash position<\/a><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
<\/div>\n\n\n\n
\n
Consult the Archives<\/a><\/div>\n<\/div>\n\n\n\n
<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

Communications Financi\u00e8res 2026 20\/02\/2026 IntegraGen \u2013 Chiffre d\u2019affaires 2025 et position de tr\u00e9sorerie 2025 29\/10\/2025 IntegraGen – Charges d’exploitation en baisse de 20% et position de tr\u00e9sorerie \u00e0 1,7 M\u20ac au 30 juin 2025 02\/07\/2025 IntegraGen – Chiffre d’affaires de 2,5 M\u20ac et position de tr\u00e9sorerie de 2,1 M\u20ac 29\/04\/2025 IntegraGen \u2013 R\u00e9sultats annuels 2024…<\/p>","protected":false},"author":1,"featured_media":0,"parent":2082,"menu_order":2,"comment_status":"closed","ping_status":"closed","template":"fullwidth-page-template","meta":{"ca_portfolio_gallery_project_year":"","ca_portfolio_gallery_client":"","ca_portfolio_gallery_skills":"","ca_portfolio_gallery_url":"","ca_portfolio_gallery_images":"","_eb_attr":"","footnotes":""},"class_list":["post-2110","page","type-page","status-publish","hentry"],"yoast_head":"\nCommunications Financi\u00e8res – IntegraGen<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/integragen.com\/en\/investisseurs\/communiques-de-presse\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Communications Financi\u00e8res – IntegraGen\" \/>\n<meta property=\"og:description\" content=\"Communications Financi\u00e8res 2026 20\/02\/2026 IntegraGen \u2013 Chiffre d\u2019affaires 2025 et position de tr\u00e9sorerie 2025 29\/10\/2025 IntegraGen – Charges d’exploitation en baisse de 20% et position de tr\u00e9sorerie \u00e0 1,7 M\u20ac au 30 juin 2025 02\/07\/2025 IntegraGen – Chiffre d’affaires de 2,5 M\u20ac et position de tr\u00e9sorerie de 2,1 M\u20ac 29\/04\/2025 IntegraGen \u2013 R\u00e9sultats annuels 2024...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/integragen.com\/en\/investisseurs\/communiques-de-presse\/\" \/>\n<meta property=\"og:site_name\" content=\"IntegraGen\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-25T15:21:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/integragen.com\/wp-content\/uploads\/2024\/07\/image-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2478\" \/>\n\t<meta property=\"og:image:height\" content=\"684\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/integragen.com\\\/investisseurs\\\/communiques-de-presse\\\/\",\"url\":\"https:\\\/\\\/integragen.com\\\/investisseurs\\\/communiques-de-presse\\\/\",\"name\":\"Communications Financi\u00e8res – IntegraGen\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/integragen.com\\\/#website\"},\"datePublished\":\"2024-08-14T10:08:01+00:00\",\"dateModified\":\"2026-02-25T15:21:06+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/integragen.com\\\/investisseurs\\\/communiques-de-presse\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/integragen.com\\\/investisseurs\\\/communiques-de-presse\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/integragen.com\\\/investisseurs\\\/communiques-de-presse\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/integragen.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investisseurs\",\"item\":\"https:\\\/\\\/integragen.com\\\/investisseurs\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Communications Financi\u00e8res\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/integragen.com\\\/#website\",\"url\":\"https:\\\/\\\/integragen.com\\\/\",\"name\":\"IntegraGen - Clinical Genomic Experts\",\"description\":\"NGS Sequencing & Bioinformatics for Pharma, Biotech & CRO\",\"publisher\":{\"@id\":\"https:\\\/\\\/integragen.com\\\/#organization\"},\"alternateName\":\"IntegraGen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/integragen.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/integragen.com\\\/#organization\",\"name\":\"IntegraGen\",\"url\":\"https:\\\/\\\/integragen.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/integragen.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/integragen.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/Logo_IntegraGen_OncoDNA.png\",\"contentUrl\":\"https:\\\/\\\/integragen.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/Logo_IntegraGen_OncoDNA.png\",\"width\":2478,\"height\":684,\"caption\":\"IntegraGen\"},\"image\":{\"@id\":\"https:\\\/\\\/integragen.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/integragen\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Communications Financi\u00e8res – IntegraGen","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/integragen.com\/en\/investisseurs\/communiques-de-presse\/","og_locale":"en_US","og_type":"article","og_title":"Communications Financi\u00e8res – IntegraGen","og_description":"Communications Financi\u00e8res 2026 20\/02\/2026 IntegraGen \u2013 Chiffre d\u2019affaires 2025 et position de tr\u00e9sorerie 2025 29\/10\/2025 IntegraGen – Charges d’exploitation en baisse de 20% et position de tr\u00e9sorerie \u00e0 1,7 M\u20ac au 30 juin 2025 02\/07\/2025 IntegraGen – Chiffre d’affaires de 2,5 M\u20ac et position de tr\u00e9sorerie de 2,1 M\u20ac 29\/04\/2025 IntegraGen \u2013 R\u00e9sultats annuels 2024...","og_url":"https:\/\/integragen.com\/en\/investisseurs\/communiques-de-presse\/","og_site_name":"IntegraGen","article_modified_time":"2026-02-25T15:21:06+00:00","og_image":[{"width":2478,"height":684,"url":"https:\/\/integragen.com\/wp-content\/uploads\/2024\/07\/image-1.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/integragen.com\/investisseurs\/communiques-de-presse\/","url":"https:\/\/integragen.com\/investisseurs\/communiques-de-presse\/","name":"Communications Financi\u00e8res – IntegraGen","isPartOf":{"@id":"https:\/\/integragen.com\/#website"},"datePublished":"2024-08-14T10:08:01+00:00","dateModified":"2026-02-25T15:21:06+00:00","breadcrumb":{"@id":"https:\/\/integragen.com\/investisseurs\/communiques-de-presse\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/integragen.com\/investisseurs\/communiques-de-presse\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/integragen.com\/investisseurs\/communiques-de-presse\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/integragen.com\/"},{"@type":"ListItem","position":2,"name":"Investisseurs","item":"https:\/\/integragen.com\/investisseurs\/"},{"@type":"ListItem","position":3,"name":"Communications Financi\u00e8res"}]},{"@type":"WebSite","@id":"https:\/\/integragen.com\/#website","url":"https:\/\/integragen.com\/","name":"IntegraGen - Clinical Genomic Experts","description":"NGS Sequencing & Bioinformatics for Pharma, Biotech & CROs","publisher":{"@id":"https:\/\/integragen.com\/#organization"},"alternateName":"IntegraGen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/integragen.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/integragen.com\/#organization","name":"IntegraGen","url":"https:\/\/integragen.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/integragen.com\/#\/schema\/logo\/image\/","url":"https:\/\/integragen.com\/wp-content\/uploads\/2024\/09\/Logo_IntegraGen_OncoDNA.png","contentUrl":"https:\/\/integragen.com\/wp-content\/uploads\/2024\/09\/Logo_IntegraGen_OncoDNA.png","width":2478,"height":684,"caption":"IntegraGen"},"image":{"@id":"https:\/\/integragen.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/integragen\/"]}]}},"_links":{"self":[{"href":"https:\/\/integragen.com\/en\/wp-json\/wp\/v2\/pages\/2110","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/integragen.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/integragen.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/integragen.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/integragen.com\/en\/wp-json\/wp\/v2\/comments?post=2110"}],"version-history":[{"count":28,"href":"https:\/\/integragen.com\/en\/wp-json\/wp\/v2\/pages\/2110\/revisions"}],"predecessor-version":[{"id":4712,"href":"https:\/\/integragen.com\/en\/wp-json\/wp\/v2\/pages\/2110\/revisions\/4712"}],"up":[{"embeddable":true,"href":"https:\/\/integragen.com\/en\/wp-json\/wp\/v2\/pages\/2082"}],"wp:attachment":[{"href":"https:\/\/integragen.com\/en\/wp-json\/wp\/v2\/media?parent=2110"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}